



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 19TH FEBRUARY 2020
AT 12.30pm

IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT (Acting Chair)
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T McKenzie (TM)	GP EL CCG
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
Dr R Singh	Consultant Cardiologist, ELHT (for 2020/020)

2020/011: APOLOGIES:

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr D Gavan (DG)	Consultant Radiologist ELHT
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG

2020/012: DECLARATION OF INTEREST

None declared – relevant to agenda items.

The following item discussed at beginning of meeting with Dr R Singh, Consultant Cardiologist in attendance.

2020/020: FORMULARY UPDATES

Ranolazine & Ivabradine

Cardiology request that Ranolazine and Ivabradine are changed from Amber to Green traffic light. Both these medications are included in NICE guidance for stable angina.

Ranolazine would be a second line option in preference to a long acting nitrate. Ivabradine would be an option after maximum dose beta blocker if it failed to control symptoms.

Dr Singh will assist with information / quick reference guide and training sessions to support GP prescribing of these medications and share resources with ELMMB to facilitate production of a 'HOT Topic'.

Dr Singh left the meeting.

Resolved: Ranolazine and ivabradine to be changed from amber to green traffic light when prescribing resources produced for primary care.

Traffic Light: GREEN

2020/013: MINUTES OF JANUARY MEETING:

Accepted as a correct record.

2020/014: MATTERS ARISING:

2019/131: Treatment of Vitamin B12 Deficiency Draft – A pathway is currently being developed with Jane Oakey from Path Lab. To be brought to ELMMB when completed.

2019/143: LMMG Recommendations (From Sept LMMG) - ADHD Shared Care Guideline – updated - the lack of compliance with shared care guideline has been raised at community paediatric directorate meeting. The paediatricians have promised to communicate with GPs and comply with the shared care document.

2019/178: LSCMMG Recommendations (From Nov LSCMMG) - Rheumatoid Arthritis High Cost drugs Pathway – updated – biosimilar names now included and is to be shared with rheumatologists for comments.

2020/015: NEW PRODUCT REQUEST – RELVAR ELLIPTA® & ANORO ELLIPTA®

Requested by Dr Hafeez, Respiratory Consultant for prophylaxis of asthma (Relvar Ellipta) and COPD (Anoro Ellipta).

Relvar Ellipta has efficacy in asthma and would be an alternative combination and device, to other Inhaled Corticosteroids/Long Acting Beta Agonists (ICS/LABA) in the current pathway.

Anoro Ellipta has efficacy in COPD and would be an alternative combination and device, to other LAMA/LABA devices in the current pathway. Trelegy Ellipta is already in the pathway at a later stage and this would be a logical initial option.

These combinations and devices are available on the LSCMMG pathways for other Lancashire CCGs.

The PCN (Primary Care Networks) are encouraging GPs to reduce MDI use in favour of DPI and the GPs at ELMMB support the addition of these devices as they would offer a DPI alternative.

Concerns were expressed from the CCG as they are encouraging the reduction of fluticasone use but the Relvar Ellipta contains fluticasone. JV to discuss with EL and BwD CCG leads and if in agreement add to formulary. If they have further concerns then bring back to a future meeting and invite Dr Hafeez to attend.

Action: JV to discuss with EL & BwD CCG leads to have agreement to include on formulary or bring back for further discussion.

2020/016: NEW PRODUCT REQUEST – MERPOENEM WITH VABORBACTAM

Requested by microbiology for treatment of infections caused by *Klebsiella pneumoniae* carbapenemase (KPC) or other carbapenemases. It is a combination of meropenem with a beta-lactamase inhibitor that has better efficacy and safety than conventional therapy for multi drug resistant KPC. Currently a combination of 2 – 3 antibiotics is used including meropenem and colistin / amikacin but there are potentially serious side effects. Use of meropenem with vaborbactam would be monotherapy, targeted for KPC infections on recommendation of consultant microbiologist only. It was approved for secondary care use only.

Resolved: Meropenem with vaborbactam approved on consultant microbiologist recommendation only.
Traffic Light: RED

2020/017: LSCMMG CONSULTATIONS (for March LSCMMG)

Amiodarone & Dronedrone Shared Care Guideline – concerns with 6 monthly ECG for primary care as many GP's would not be confident to interpret & therefore refer back to secondary care. Recommend to add that as amiodarone's has a long half-life the monitoring should go beyond when it is discontinued.

VACocast Diabetic Boot – in principle is reasonable but should it be Red as patients need to be under care of diabetic team.

Resolved: Comments to be sent to LSCMMG

2020/018: LSCMMG Recommendations (From Jan LSCMMG)

Dementia Medicines Prescribing Information Sheet – updated – in line with NICE. Accepted as written for ELHE.

Riluzole Patient Information Leaflet - updated – acknowledged by ELHE.

2020/019: JOINT COMMITTEE OF CCG's COMMISSIONING DECISIONS (From Jan LSCMMG)

The following decisions have been approved by the Joint committee of CCG's and are for information. The decisions will apply in ELHE.

Cariprazine New Medicine Recommendation – Amber 1

Octreotide/Lanreotide for Recurrent GI Bleeding Disorders New Medicine Recommendation – Red, Blueteq form is required to be completed before initiation.

Cyanocobalamin tablets New Medicine Recommendation – Black.

Azathioprine for Myasthenia Gravis New Medicine Recommendation – Amber 1

2020/020: FORMULARY UPDATES

Levofloxacin – used second line for H.Pylori. NICE guidance recommends levofloxacin as monotherapy for treatment of CAP and HAP in place of teicoplanin and ciprofloxacin. To be added to formulary. **Traffic Light: GREEN (oral), RED (iv)**

Voriconazole – is used following sensitivities for genital / oral thrush when infection has not resolved with other agents (nystatin & fluconazole). Microbiologist would like a change to Amber to allow GPs to prescribe for '2 weeks only' on the advice of microbiologist only. No monitoring required for 2 week course. To be changed from red to Amber. **Traffic Light: AMBER**

Nitrofurantoin Liquid – remain Amber but amend wording in formulary to state 'if cultures and sensitivities confirm', the microbiologist does not need to be contacted directly. As it is very expensive use should only be for paediatrics where other agents are not suitable and it is not possible to provide the required dose with tablet formulation. JV to add suitable wording to GP prescribing system. **Traffic Light: AMBER**

Aerochamber Plus Flow-Vu Anti-Static Device –device added to formulary as an option when a spacer device is required. **Traffic Light: GREEN**

Phenobarbitone liquid 50mg/5mL, Chloral hydrate liquid 500mg/5mL, Chlorothiazide liquid 250mg/5mL, Sodium bicarbonate 1mmol/mL oral solution – request from paediatrics to change to Amber. CCG have safety and price concerns with these products and IMOT should be used for prescribing and supply. Remain as Red traffic light and check if they are being referred correctly to IMOT or are being referred to consultants for supply. **Traffic Light: RED**

Oxycodone PR tablets – add Oxypro® as a cost effective branded generic to options for prolonged release oxycodone. **Traffic Light: GREEN**

Sandocal to CaCit – remove sandocal tablets from formulary as they are discontinued. Added CaCit to formulary as a calcium option, as it also can be used for small doses in paediatrics. **Traffic Light: GREEN**

Resolved: Formulary to be updated as above

2020/021: CARE HOMES: REPEAT MEDICATION ORDERING USING Proxy EMIS ACCESS

The care home guidance is to facilitate care home staff to order medication on behalf of residents. Guidance acknowledged.

Resolved: Repeat medication ordering guidance for care home staff acknowledged.

2020/022: NICE RECOMMENDATIONS (from Jan)

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [TA617] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618) **Traffic Light: BLACK**

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619) is recommended as an option by NICE. Approved in line with NICE.

Cancer drugs Fund

Traffic Light: RED

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621) is not recommended as an option by NICE.

Traffic Light: BLACK

STANDING ITEMS

2020/023: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES - January 2020

Minutes acknowledged

2020/024: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Oct 2019

Minutes acknowledged

Any Other Business

Topiramate for migraine prophylaxis is included as a first line option in NICE guidance. Formulary to be amended to Green for migraine. Remain Amber for epilepsy.

Traffic Light: GREEN (migraine), AMBER (epilepsy)

DATE OF NEXT MEETING – Wednesday 18th March 2020 12.30pm, Seminar Room 4, Learning & Development centre, RBH

2020 Meetings – All on 3rd Wednesday of the month at 12.30pm – 2pm

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 19TH FEBRUARY 2020

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed	LR/JV	Feb 20
2019/178	LSCMMG Recommendations (From Nov LSCMMG) - Rheumatoid Arthritis High Cost drugs Pathway – updated - biosimilar brand names added, to be sent to rheumatologists for comments	LR / JV	Feb 20
2020/015	New Product request – Relvar Ellipta® & Anoro Ellipta® - Discuss with CCG leads and bring back to ELMMB if further discussion required	JV	Mar 20
2020/020	Formulary Updates – Ranolazine & Ivabradine – Hot Topic to support GP prescribing to be produced with assistance from Dr Singh	JV	Apr 20
2020/020	Formulary Updates - Phenobarbitone liquid 50mg/5mL, Chloral hydrate liquid 500mg/5mL, Chlorothiazide liquid 250mg/5mL, Sodium bicarbonate 1mmol/mL oral solution – Check referrals are going to IMOT not paediatricians	VG/CW JV	Mar 20